Close Menu

NEW YORK ─ Massachusetts Institute of Technology spinout Glympse Bio said on Wednesday that it has closed an oversubscribed $46.7 million Series B financing round.

The Cambridge, Massachusetts-based firm said it anticipates using the proceeds to support the continued development of its biosensor platform for the diagnosis of cancers, infectious diseases, and fibrotic diseases such as non-alcoholic steatohepatitis (NASH).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.